|
Post by akemp3000 on Jul 15, 2019 10:28:08 GMT -5
This will raise awareness.. but the same problems exist .patient goes to doc who either doesn't understand Afrezza OR refuses to prescribe.. = no success.. low retention. I think we all agree that all of these issues must be addressed however possible. Only Al thought this would be easy
|
|
|
Post by od on Jul 15, 2019 10:32:18 GMT -5
I don't see anything there that didn't exist before for Mannkind. What does goodrx get out of the deal -- advertising dollars from Mannkind? Some information about GoodRx: www.goodrx.com/how-goodrx-works"GoodRx is free for consumers, and we do not require that you create an account to search for prices and receive discounts. We do not collect your personal information. We make money from advertisements on our site and referral fees." AND (this is a good read): www.cnbc.com/2019/05/15/goodrx-app-has-saved-americans-more-than-10-billion-on-prescriptions.html"GoodRx also has a monthly subscription program, GoodRx Gold, which offers additional discounts." Perhaps Mannkind delayed joining GoodRx before now because it wanted to make sure its discount model was sufficiently scalable before doing so? Or, perhaps, GoodRx delayed Mabnnkind's participation until it was convinced that Mannkind's program was viable? IDK. "Or, perhaps, GoodRx delayed Mabnnkind's participation until it was convinced that Mannkind's program was viable?" Know this to be true -- GoodRx would have been happy to commence an advertising/marketing program for Afrezza the day it was approved by the FDA. MNKD is paying for the program.
|
|
|
Post by sweedee79 on Jul 15, 2019 10:32:48 GMT -5
Awareness is great.. but Everytime we lose a patient because the doc didn't prescribe the right dose isn't good.. it does damage .. some are saying our retention rate is 30%..
What happens when the other 70% go away telling others Afrezza stinks..
Unless Mnkd can solve the underlying problems this marketing plan doesn't work very well.. or we need a partner.
|
|
|
Post by goyocafe on Jul 15, 2019 10:38:12 GMT -5
So a new partnership is announced with GoodRx. Do you think GoodRx would be kind enough to update the description on Afrezza to make it a bit more appealing: "Afrezza (insulin) is used to treat diabetes mellitus, including diabetes type 1 and diabetes type 2. This drug is less popular than comparable drugs. There is currently no generic alternative for Afrezza, but less expensive biosimilar versions may be available in the future. It is not covered by most Medicare and insurance plans, but manufacturer and pharmacy coupons can help offset the cost. The lowest GoodRx price for the most common version of Afrezza is around $972.73, 17% off the average retail price of $1,183.73. Compare insulins." www.goodrx.com/afrezza
|
|
|
Post by rtmd on Jul 15, 2019 10:50:38 GMT -5
A quick google shows a lot of goodrx partners, but I couldn't find a single pharma among them. I wonder why that would be the case.
|
|
|
Post by od on Jul 15, 2019 10:55:11 GMT -5
A quick google shows a lot of goodrx partners, but I couldn't find a single pharma among them. I wonder why that would be the case. Partnership, really? It is an advertising/marketing campaign.
|
|
|
Post by mnkdfann on Jul 15, 2019 11:26:05 GMT -5
A quick google shows a lot of goodrx partners, but I couldn't find a single pharma among them. I wonder why that would be the case. Perhaps enough pharmacies, PBMs, health plans, etc., participate and hence get the drugs of big parma listed on GoodRx, without the manufacturers of those needing to bother themselves. More on GoodRx: support.goodrx.com/hc/en-us/articles/360001302523-How-does-GoodRx-make-money-Today, GoodRx makes money in a few ways:
We provide technology to businesses and insurance plans to help employees/members save money on their prescriptions, so that they can help their members understand how much they’ll pay for their prescriptions and find new ways to save. We show ads on our website and apps. These ads do not have any impact on which prices, pharmacy listings or drugs we display. Some partners (typically pharmacies, health plans, manufacturers or pharmacy benefit managers) pay us referral fees when a particular discount is used. GoodRx Gold, our subscription service, offers often lower prices at select pharmacies in exchange for a monthly fee. It’s worth mentioning that GoodRx is not “pay-to-play” - pharmacies and manufacturers are not required to pay to appear on GoodRx, and we list thousands of prices and discounts where we receive no compensation. It’s our goal to gather as many prices and discounts as we can, regardless of any financial incentive.
|
|
|
Post by cretin11 on Jul 15, 2019 11:30:59 GMT -5
So how much is this costing MNKD?
|
|
|
Post by od on Jul 15, 2019 11:32:01 GMT -5
A quick google shows a lot of goodrx partners, but I couldn't find a single pharma among them. I wonder why that would be the case. Perhaps enough pharmacies, PBMs, health plans, etc., participate and hence get the drugs of big parma listed on GoodRx, without the manufacturers of those needing to bother themselves. More on GoodRx: support.goodrx.com/hc/en-us/articles/360001302523-How-does-GoodRx-make-money-Today, GoodRx makes money in a few ways:
We provide technology to businesses and insurance plans to help employees/members save money on their prescriptions, so that they can help their members understand how much they’ll pay for their prescriptions and find new ways to save. We show ads on our website and apps. These ads do not have any impact on which prices, pharmacy listings or drugs we display. Some partners (typically pharmacies, health plans, manufacturers or pharmacy benefit managers) pay us referral fees when a particular discount is used. GoodRx Gold, our subscription service, offers often lower prices at select pharmacies in exchange for a monthly fee. It’s worth mentioning that GoodRx is not “pay-to-play” - pharmacies and manufacturers are not required to pay to appear on GoodRx, and we list thousands of prices and discounts where we receive no compensation. It’s our goal to gather as many prices and discounts as we can, regardless of any financial incentive. "It’s worth mentioning that GoodRx is not “pay-to-play” - pharmacies and manufacturers are not required to pay to appear on GoodRx, and we list thousands of prices and discounts where we receive no compensation. It’s our goal to gather as many prices and discounts as we can, regardless of any financial incentive." Afrezza has always been listed on GoodRx. The banners now running are paid advertisements.
|
|
|
Post by goyocafe on Jul 15, 2019 12:09:38 GMT -5
So a new partnership is announced with GoodRx. Do you think GoodRx would be kind enough to update the description on Afrezza to make it a bit more appealing: "Afrezza (insulin) is used to treat diabetes mellitus, including diabetes type 1 and diabetes type 2. This drug is less popular than comparable drugs. There is currently no generic alternative for Afrezza, but less expensive biosimilar versions may be available in the future. It is not covered by most Medicare and insurance plans, but manufacturer and pharmacy coupons can help offset the cost. The lowest GoodRx price for the most common version of Afrezza is around $972.73, 17% off the average retail price of $1,183.73. Compare insulins." www.goodrx.com/afrezzaHere you go Rose, MC, and whoever is making successful partnerships really work in our favor. 5 minutes and no charge. Afrezza (insulin) is used to treat diabetes mellitus, including diabetes type 1 and diabetes type 2. Post approval studies reveal less hyperglycemia and hypoglycemia and greater time in range than other meal time insulins. There is currently no generic alternative for Afrezza, but less expensive biosimilar versions may be available in the future. Afrezza is covered by most insurance with the possibility of a prior authorization required by some plans. Manufacturer and pharmacy coupons can help offset the cost and the manufacturer offers services to help with filling prescriptions. The lowest GoodRx price for the most common version of Afrezza is around $972.73, 17% off the average retail price of $1,183.73. Compare insulins.
|
|
|
Post by rockstarrick on Jul 15, 2019 12:09:38 GMT -5
Awareness is great.. but Everytime we lose a patient because the doc didn't prescribe the right dose isn't good.. it does damage .. some are saying our retention rate is 30%.. What happens when the other 70% go away telling others Afrezza stinks.. Unless Mnkd can solve the underlying problems this marketing plan doesn't work very well.. or we need a partner. It's not even a ”Dr prescribing the wrong dose” problem, its an ”its ok to take another puff if you need it” problem. PWD need to know that Afrezza and everything about it is completely different than other mealtime options. To be successful with afrezza, you need to forget most everything you've learned about managing diabetes with RAA’s The timing in and out, is completely different than any other prandial insulin product ever, and understanding the significance of this is crucial. Afrezza is too fast to take prior to a meal, if you take it 15 minutes prior and are a slow eater, you won't get the same results as someone who takes it after the start of the meal, and eats like a hog 😉 Pretty incredible that afrezza is so fast in, that 15 minutes either way, (dosing), will drastically change how it works for those using it. Understanding the fact that afrezza is ”out” before digestion is complete, and that this greatly reduces the risk of hypoglycemia, but also increases the need for a second dose is crucial. How we are included in the same class of RAA’s is beyond stupid, and those in the Industry that aren't bright enough to see this should be shown the door. If I were King for a day 😎
|
|
|
Post by rtmd on Jul 15, 2019 12:19:45 GMT -5
Awareness is great.. but Everytime we lose a patient because the doc didn't prescribe the right dose isn't good.. it does damage .. some are saying our retention rate is 30%.. What happens when the other 70% go away telling others Afrezza stinks.. Unless Mnkd can solve the underlying problems this marketing plan doesn't work very well.. or we need a partner. It's not even a ”Dr prescribing the wrong dose” problem, its an ”its ok to take another puff if you need it” problem. PWD need to know that Afrezza and everything about it is completely different than other mealtime options. To be successful with afrezza, you need to forget most everything you've learned about managing diabetes with RAA’s The timing in and out, is completely different than any other prandial insulin product ever, and understanding the significance of this is crucial. Afrezza is too fast to take prior to a meal, if you take it 15 minutes prior and are a slow eater, you won't get the same results as someone who takes it after the start of the meal, and eats like a hog 😉 Pretty incredible that afrezza is so fast in, that 15 minutes either way, (dosing), will drastically change how it works for those using it. Understanding the fact that afrezza is ”out” before digestion is complete, and that this greatly reduces the risk of hypoglycemia, but also increases the need for a second dose is crucial. How we are included in the same class of RAA’s is beyond stupid, and those in the Industry that aren't bright enough to see this should be shown the door. If I were King for a day 😎 I suspect that most do understand "the fact that afrezza is ”out” before digestion is complete " and that is an issue. Unless you have a CGM -- which, as I understand, most type 1s still don't -- you're stuck having to remember doing yet another painful fingerstick 1-2 hours after a meal in order to confirm the response. I can see where that would put off a lot of patients.
|
|
|
Post by sweedee79 on Jul 15, 2019 15:00:33 GMT -5
It is about dose also.. as RAA and Afrezza aren't the same unit for unit as was stated initially and this was how the trials were ran for approval.. it amazes me that we ever got approval in the first place.
You need at least 1.5 or 2Xs Afrezza compared to RAA.. everything about this was botched from the beginning..we needed superiority trials.. instead we ended up noninferior.. and don't have the cash ..
It's all a mess.. and we are running out of time.. those who can't see this are blind. To continue with the same marketing will not work.. the climb up will be slow.. in business that's not a good thing..
So the solution is partner with large BP or think out of the box.. I hate to say it because I know how some feel around here.. but Vdex is a solution..
And I havent resorted to slamming MC.. I'm just saying his marketing isn't working and this Goodrx deal is another example of doing the same old thing that isn't going to work unless underlying problems are solved first.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 15, 2019 15:00:52 GMT -5
Awareness is great.. but Everytime we lose a patient because the doc didn't prescribe the right dose isn't good.. it does damage .. some are saying our retention rate is 30%.. What happens when the other 70% go away telling others Afrezza stinks.. Unless Mnkd can solve the underlying problems this marketing plan doesn't work very well.. or we need a partner. It's coming but we have to do the Recapitalization first. We need the covenants removed and extra cash. Expect ALL DEBT to be refinanced and extended until 2026 with much better terms.
|
|
|
Post by cedafuntennis on Jul 15, 2019 15:10:08 GMT -5
That should have been done FIRST, way before wasting millions on the TV advertising with stupid ads. I keep saying that it costs 30c to keep a client and 3$ to add a new one. But these multi-million dollar salary people don't give a hoot about what makes sense and stick to what other multi billion dollar huge pharmas do. Last I checked we are not and we have to be flexible and nimble and wasting precious dollars on such employees and strategies is not helpful at all.
|
|